Substituted {5-methoxy-6-[(5-methoxypyridin-2-yl)methoxy]pyridin-3-yl} methyl compounds as CSF-1R inhibitors
Grant
US12577229B2
Kind: B2
Mar 17, 2026
Assignee
Eli Lilly and Company
Inventors
Simon James Richards
Abstract
The present invention provides a compound of Formula I: Formula I or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the compound and to methods of using the compound to treat physiological disorders.
CPC Classifications
C07D 401/14
Filing Date
2021-04-23
Application No.
17997258
Claims
8